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Introduction {#sec1}
============

Bacteria have evolved multiple defense strategies to resist bacteriophage infection ([@bib25], [@bib26], [@bib37]). The clustered regularly interspaced short palindromic repeats (CRISPR) and their CRISPR-associated (Cas) systems are the first identified and only adaptive immunity against the foreign invaders and mobile genetic elements (MGEs) via *cas* genes and CRISPR arrays ([@bib2], [@bib33], [@bib35]). The CRISPR arrays consist of DNA remnants from foreign invaders (mostly from phages) to generate CRISPR RNAs (crRNAs) that target nucleic acids in a sequence-specific manner ([@bib16]). Cas proteins play a critical role in mediating the acquisition of foreign sequences into a CRISPR array (adaptation or immunization) ([@bib19], [@bib36]), facilitating the maturation of crRNAs ([@bib11]), and counteracting invasion of MGEs, DNA ([@bib14]), or RNA ([@bib13]). Both immunization and immunity processes require activation of CRISPR-Cas systems. Currently, two distinct classes of CRISPR-Cas systems have been identified, which are further divided into a series of subtypes based on their distinct Cas effector machineries with substantial differences in targeting mechanisms ([@bib28], [@bib31]). New CRISPR-Cas systems have been continuously discovered ([@bib7], [@bib47]). The current understanding of the adaptive immunity is that CRISPR-Cas systems enable bacteria to distinguish nucleic acids between self and foreign sources, relying on the recognition of spacers and protein-mediated protospacer adjacent motif (PAM) to avoid autoimmunity ([@bib18], [@bib42], [@bib55], [@bib54]). CRISPR-Cas systems are important for adaptive immunity for bacteria or archaea to survive in adverse environments by combatting numerous phages; however, many intriguing questions remain to be answered ([@bib27]). For instance, how do bacteria regulate CRISPR-Cas systems to shape and balance host defense and homeostasis?

To effectively defend against phages or MGEs, bacterial CRISPR-Cas systems rapidly evolved through horizontal transfer of complete loci or individual modules, resulting in functional diversity ([@bib37]). To promote invasive potency, phages also produce inhibitors to enhance the ability to lyse host bacterium or effectively integrate into bacterial genomes ([@bib37], [@bib44]). Studies revealed that phages encode proteins to inhibit or directly interact with different Cas proteins to prevent the functionality of CRISPR-Cas systems ([@bib3], [@bib41], [@bib48]). However, little is presently known about whether CRISPR-Cas systems can be regulated by bacterial own genes.

Quorum sensing (QS) is known not only to govern bacterial virulence but also to regulate communication between bacterial cells and organize collective behaviors in bacterial populations ([@bib39]). Recently, QS signaling was found to mediate the expression and activity of multiple CRISPR-Cas systems ([@bib22], [@bib40]). These QS effects on prokaryotic adaptive immune systems are strongly associated with cell density, because increased diversity of CRISPR spacers within communities restricts the success of phage escape mutants ([@bib51]). Modulating CRISPR-Cas immunity regulated by QS opens up a question of how bacterial signaling controls the CRISPR-Cas system, but how bacterial genes finely regulate CRISPR-Cas system at the molecular levels remains uncertain ([@bib21], [@bib34], [@bib46]). We recently identified a novel QS regulator, CdpR (ClpAP-degradation and pathogenicity regulator), which negatively modulates the *Pseudomonas* quinolone signal (PQS) system in PAO1 strain ([@bib57]). PQS plays a role in the regulation of multiple genes involved in bacterial QS ([@bib5], [@bib17]). PQS and QS along with a group of transcriptional regulators form a complex regulatory network ([@bib9]). However, whether CdpR can directly alter QS levels and function remains elusive. Furthermore, whether CdpR can influence the expression, activity, and immunity of CRISPR-Cas is completely unknown.

Here, we explored the role of CdpR in type I-F CRISPR-Cas system with *Pseudomonas aeruginosa* UCBPP-PA14 strain (denoted PA14) and reveal that CdpR represses the immunization and immunity potency of CRISPR-Cas via QS to impede the expression, activity, and spacer acquisition of the CRISPR-Cas system. The CdpR-mediated regulation of CRISPR-Cas influences phage infection by Vfr-mediated *cas1* promoter binding and expression. Hence, we propose that CdpR may prevent bacterial self-reactivity via blockade of CRISPR-mediated endogenous cleavage. These findings enlist CdpR as the first endogenous negative regulator of CRISPR-Cas systems to maintain the balance between host defense and self-targeting of CRISPR-Cas systems. Together, our studies highlight the role of precise regulation of CRISPR-Cas in the co-evolution of bacteria with their invaders, phages, to maintain an active host defense without harming their own genes.

Results {#sec2}
=======

CdpR Represses the Activity of CRISPR-Cas Interference and Spacer Acquisition {#sec2.1}
-----------------------------------------------------------------------------

Recent studies imply that both bacterial genes and intracellular signals may regulate the expression and function of CRISPR-Cas. Since CdpR is a newly discovered regulator of QS genes and the QS systems can regulate CRISPR-Cas, we hypothesize that CdpR may modulate type I-F CRISPR-Cas systems in the PA14 strain. As expected, compared with the PA14-WT strain, the signal-deficient *cdpR* mutant (PA14-Δ*cdpR*) exhibited increased expression of Cas surveillance complex ([Figure 1](#fig1){ref-type="fig"}A). In agreement, expression of the Cas surveillance complex by complementation with CdpR (PA14-Δ*cdpR*/*p-cdpR*) was restored to the PA14-WT level. This result demonstrated that the expression of CRISPR-Cas loci is downregulated by CdpR.Figure 1CdpR Represses the Activity of CRISPR-Cas System against Phage Infection(A) Heatmap for *csy1-4*, *cas1*, and *cas3*-related mRNA transcripts in *P. aeruginosa* PA14-WT, PA14-Δ*cdpR*, and PA14-Δ*cdpR/p-cdpR* with the same cell density quantified by qRT-PCR. Data were normalized with 16sRNA expression as an internal control.(B) The type I-F CRISPR-Cas locus in PA14. Experiments utilizing a non-targeted plasmid and two CRISPR-targeted plasmids (denoted CR1-sp1 and CR2-sp1) that contain a protospacer matching spacer 1 in CRISPR array 1 and 2, respectively.(C) Transformation efficiency of CRISPR-targeted plasmids in PA14-WT or PA14-Δ*cdpR* mutant.(D) New spacer acquisition (CRISPR expansion) in CRISPR array 1 or 2 locus evaluated by PCR in PA14-WT and mutant strains. Strains harbored the primed plasmid containing a seed mutation to promote adaptation. Naïve represents the native CRISPR arrays in the PA14 genome.(E) Diagram of crRNA~CR2-sp1~ in *P. aeruginosa* PA14 type I-F CRISPR-Cas systems interacting with DMS3-T255C and DMS3~100%~ sequences. Lines denote Watson-Crick base pairing between crRNA~CR2-sp1~ and its phage target sequences in the DMS3-T255C and DMS3~100%~. PAM is shown within a shadowed box.(F) DMS3~100%~ and DMS3-T255C phages grew on bacterial lawns of PA14-WT, PA14-Δ*cdpR*, PA14-Δ*cdpR/p-cdpR*, and PA14-ΔTCR.(G) Acquisition of new spacer sequences with phage DMS3-T255C infection in PA14-WT and mutant strains analyzed by qPCR.Data shown are the means ±SEM (n = 3) (one-way ANOVA plus Tukey test, \*\*p \< 0.01; \*p \< 0.05).

To determine whether the function of CRISPR-Cas systems is also modulated by CdpR, we measured the effect of CRISPR-Cas on eliminating CRISPR-targeted or CRISPR-untargeted plasmid in the PA14-Δ*cdpR* strain. We generated two CRISPR-targeted plasmids, CR1-sp1 and CR2-sp1 ([@bib8]), that possess a targeted protospacer (a sequence complementary to a spacer in CRISPR array 1 or 2, respectively) flanked by a cognate PAM ([Figure 1](#fig1){ref-type="fig"}B). We quantified the retention of plasmids in the PA14-WT and PA14-Δ*cdpR* strains with shaking for 5 h according to a previous report ([@bib22]). There was no loss of untargeted plasmid in all strains ([Figure S1](#mmc1){ref-type="supplementary-material"}A), whereas loss of CR1-sp1 and CR2-sp1 plasmids occurred in PA14-WT, PA14-Δ*cdpR*, and PA14-Δ*cdpR*/*p-cdpR* compared with PA14-ΔTCR lacking *cas* genes ([Figure S1](#mmc1){ref-type="supplementary-material"}B), indicating that plasmid loss resulted from CRISPR-Cas interference, consistent with the previous reports that CRISPR-Cas systems are required for foreign DNA interference ([@bib2], [@bib35]). Meanwhile, this loss was significantly influenced by CdpR, showing that CdpR inhibits the efficiency of CRISPR-Cas-mediated interference ([Figure S1](#mmc1){ref-type="supplementary-material"}B). We investigated whether CdpR influences CRISPR-Cas-mediated elimination of an incoming genetic element that resembles a phage attack, which can be assessed by plasmid transformation efficiency of the PA14-WT and mutant strains. The transformation inhibition in the PA14-Δ*cdpR* strain was more efficient than that in the PA14-WT strain. In addition, complementation of *cdpR* restored the repression of CRISPR-Cas activity ([Figure 1](#fig1){ref-type="fig"}C). Collectively, these results affirm that CdpR represses CRISPR-Cas immunity, thereby hampering host defense against invasive elements.

Next, we questioned whether spacer acquisition is also regulated by CdpR. As the frequency of spacer acquisition can be increased by challenging bacteria with protospacer containing elements or primed process ([@bib10]), we constructed a primed plasmid by inserting a protospacer that targets CRISPR array 2 spacer 1 containing a single base mutation ([Figure 1](#fig1){ref-type="fig"}B). We detected new spacer acquisition in the CRISPR array locus and found that, although spacer acquisition occurred in both the PA14-WT and PA14-Δ*cdpR* strains, adaptation in the PA14-Δ*cdpR* mutant was increased vs. the PA14-WT strain, which was reversed to the WT level in the complemented strain, PA14-Δ*cdpR*/*p-cdpR* ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}C). This result suggests that CdpR represses CRISPR-Cas activity and blocks spacer acquisition. In addition, we found that the adaptation frequency on the CRISPR array 2 locus was higher than that on the CRISPR array 1 locus ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}C), consistent with a previous study ([@bib56]). Collectively, these findings clearly establish that CdpR is a negative regulator for inhibiting the expression, interference, and adaptation of *P*. *aeruginosa* CRISPR-Cas systems.

*CdpR*-Deletion Mutation Enhances CRISPR-Cas-Mediated Immunity against Phage Invasion {#sec2.2}
-------------------------------------------------------------------------------------

CRISPR-Cas systems are important for bacteria to defend against phage invasion. To assess whether CdpR plays a role in phage infection, we measured plaque-forming efficiency of CRISPR-sensitive phage DMS3-T255C and DMS3~100%~ bearing a protospacer that is partially or completely (100%) complementary to the spacer portion of crRNA~CR2-sp1~ in PA14 ([Figure 1](#fig1){ref-type="fig"}E), whereas wild-type DMS3 phage is CRISPR-insensitive ([@bib8]). Phage DMS3~100%~ failed to replicate on the PA14-WT, PA14-Δ*cdpR*, and PA14-Δ*cdpR*/*p-cdpR* strains because of the adaptive immunity of CRISPR-Cas systems but was able to replicate on the CRISPR-Cas deficient PA14-ΔTCR strain ([Figure 1](#fig1){ref-type="fig"}F). The DMS3-T255C phage on the PA14-WT strain could form plaques robustly, whereas the DMS3~100%~ displayed at least a 10,000-fold lower plaque efficiency than the DMS3-T255C ([@bib8]). Notably, we observed a low plaquing efficiency of DMS3-T255C on the PA14-Δ*cdpR* compared with that on the PA14-WT strain ([Figure 1](#fig1){ref-type="fig"}F). Remarkably, expression of the *cdpR* gene led to a marked increase in the plaquing efficiency of DMS3-T255C. Furthermore, new spacer acquisition was increased in the PA14-Δ*cdpR* strain compared with the PA14-WT strain ([Figure 1](#fig1){ref-type="fig"}G). Taken together, these data indicate that *cdpR*-deficiency mutation attenuates plaquing efficiency owing to its production of more potent CRISPR-Cas activity and that CdpR also negatively regulated CRISPR-Cas function during phage infection.

CdpR Represses CRISPR-Cas Regulation via QS Signals {#sec2.3}
---------------------------------------------------

CdpR was identified as a virulence regulator of the PQS in *P*. *aeruginosa* PAO1 strain missing CRISPR-Cas systems ([@bib57]). Bacteria communicate through QS systems to coordinate cooperative behaviors, which is essential for population fitness and invasion of hosts. We speculated that the QS circuit is associated with CdpR\'s effects on CRISPR-Cas systems in PA14 strains. Previous reports indicate that bacterial strains use chemical communication via QS systems to modulate CRISPR-Cas ([@bib22], [@bib40]). In agreement, the QS circuit regulates the type I-F CRISPR-Cas systems by adjusting the expression of multiple Cas surveillance complexes at a high cell density in PA14 strains ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Furthermore, there were significantly increased QS-dependent transcripts of *lasI*/*rhlI* and other regulators (*bfiS*, *bfiR*, *bfmS*, *bfmR*, *exsA*, *gacS*, *gacA*, *hptB*, *rpoS*, and *sagS*, whose accumulation is associated with QS systems at a high cell density) in the PA14-Δ*cdpR* mutant compared with the PA14-WT strain, but these were restored to the WT levels in the P14-Δ*cdpR*/*p-cdpR* strain ([Figure S2](#mmc1){ref-type="supplementary-material"}C). These responsive genes are diverse ranging from QS regulation to T3SS and small RNA regulators. We postulate that CdpR may repress adaptive immunity of CRISPR-Cas loci through QS signaling. To test this notion, we used the QS inhibitor baicalein ([@bib30]) to treat the PA14-Δ*cdpR* background strain, not QS inhibitor meta-bromo-thiolactone (mBLT) owing to binding and inhibiting LasR and RhlR that showed no change in the *cdpR* mutant strain compared with the WT strain ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Interestingly, baicalein abolished the positive effect of QS signals on *cas* modules and altered *csy* expression ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). Furthermore, the interference capability of these two target plasmids on the CdpR-dependent CRISPR-Cas activity was also inhibited by baicalein ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). Moreover, the QS inhibitor affected CdpR-mediated transformation inhibition ([Figure 2](#fig2){ref-type="fig"}B). Finally, to address whether QS systems regulate spacer acquisition by CRISPR-Cas systems, we found that baicalein inhibited the efficiency of CRISPR adaptation to acquire new spacers via CdpR ([Figures 2](#fig2){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}D), indicating that CdpR-mediated reduction of CRISPR-Cas activity represses the generation of immune memory by halting spacer acquisition through inhibition of QS systems. Collectively, these results imply that CdpR-mediated QS signaling is required for the control of CRISPR-Cas activity in PA14.Figure 2CdpR Mediates Repression of CRISPR-Cas System via Quorum Sensing(A) Heatmap for CRISPR-Cas expression in PA14-Δ*cdpR* background with or without 100 μM QS inhibitor baicalein.(B) Transformation efficiency of PA14-Δ*cdpR* background at high cell density with or without baicalein.(C) Integration of new spacers into CRISPR loci was detected in PA14-Δ*cdpR* strains with or without baicalein.(D) Retention assay of transformation efficiency of phage DMS3-T255C infection with PA14-Δ*cdpR* background with baicalein.(E) Ability of phage DMS3-T255C to infect *cdpR*-deficiency mutant strains with or without baicalein.(F) Integration of new spacers into a CRISPR array locus of PA14-Δ*cdpR* strain detected by PCR in the presence or absence of baicalein.(G) Schematic of CdpR represses CRISPR-Cas immune response, including immunization and immunity, via QS.Data shown are the means ± SEM (n = 3) (one-way ANOVA plus Tukey test, \*\*p \< 0.01; \*p \< 0.05).

We further investigated whether CdpR-mediated regulation of CRISPR-Cas systems is dependent on QS regulators LasI/RhlI. Double mutations of Δ*lasI*/Δ*rhlI* negatively affected the expression of *cas* genes ([Figure S4](#mmc1){ref-type="supplementary-material"}A), consistent with the previous report ([@bib22]). We generated two Δ*cdpR*/Δ*lasI*, Δ*cdpR*/Δ*rhlI* double mutants and one Δ*cdpR*/Δ*lasI*/Δ*rhlI* triple mutant in the PA14 background. The increase of *cas1*, *cas3*, and *csy1-4* expression in PA14-Δ*cdpR* was abolished by double deletion of *lasI*/*rhlI* ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Furthermore, compared with that in the PA14-Δ*cdpR* strain, expansion of CRISPR arrays ([Figure S4](#mmc1){ref-type="supplementary-material"}C) and interference of CRISPR-Cas systems ([Figure S4](#mmc1){ref-type="supplementary-material"}D) were decreased in the PA14-Δ*cdpR*/Δ*lasI*/Δ*rhlI* strain. Collectively, these findings imply that CdpR-mediated QS signaling, especially LasI/RhlI, is required for the control of CRISPR-Cas activity in PA14.

To assess the relationship between QS systems and the consequences of CdpR on CRISPR-Cas function in phage infection, we detected the effect of CdpR on CRISPR-Cas function in the presence or absence of the QS inhibitor. Colony forming units (CFUs) of PA14-Δ*cdpR* treated with baicalein showed a 1.654-fold reduction of transformation efficiency compared with DMSO-treated controls ([Figure 2](#fig2){ref-type="fig"}D). Moreover, the plaquing efficiency of DMS3-T255C on the baicalein-treated PA14-Δ*cdpR* mutant was higher than that of DMSO-treated controls ([Figure 2](#fig2){ref-type="fig"}E). In addition, inhibiting QS signaling reduced the spacer acquisition in the PA14-Δ*cdpR* strain following DMS3-T255C infection ([Figure 2](#fig2){ref-type="fig"}F). These results indicate that QS participates in the inhibition of CdpR in CRISPR-Cas function against phage infection. Taken together, our findings suggest that CdpR broadly represses CRISPR-Cas immune responses, including immunization and immunity, via QS signaling to resist phage infection ([Figure 2](#fig2){ref-type="fig"}G).

Vfr Is Required for Regulating CRISPR-Cas Systems by CdpR {#sec2.4}
---------------------------------------------------------

*P*. *aeruginosa* possesses one of the most sophisticated QS systems of all bacterial species, which coordinate a group of transcriptional regulators (such as VqsR, QscR, VqsM, Vfr, and RpoN) to form a complex regulatory network ([@bib9]). To explore the mechanism of how CdpR controls CRISPR-Cas adaptive immunity via the QS signaling, we performed bioinformatic analysis of the consensus-binding motif of these QS transcription regulators in the promoter region of *cas* operon and found a putative *v*irulence *f*actor *r*egulator (Vfr)-binding *cis*-response elements (CREs) in the *cas1* promoter that are homologous to the Vfr consensus-binding site (5′-ANWWTGNGAWNYAGWTCACAT-3′) ([@bib15]) ([Figure 3](#fig3){ref-type="fig"}A). We identified that Vfr is essential for modulating adaptation and interference ([Figures 3](#fig3){ref-type="fig"}B--3D). Both phages DMS~100%~ and DMS3-T255C showed lower plaquing efficiency on the PA14-WT strain than on the PA14-Δ*vfr* strain ([Figure 3](#fig3){ref-type="fig"}E), indicating that Vfr regulated CRISPR-Cas immunity during phage infection. Vfr was previously implicated in the regulation of a wide range of promoters ([@bib15]). To further test whether Vfr regulates the *cas* operon, we investigated *cas1* promoter activity in the PA14-WT and PA14-Δ*vfr* strains in the entire growth period. Remarkably, the *cas1* promoter activity was significantly reduced in the PA14-Δ*vfr* strain ([Figure 3](#fig3){ref-type="fig"}F) and complementation of *vfr* to the PA14-Δ*vfr* mutant restored to the levels of the WT strain ([Figure 3](#fig3){ref-type="fig"}G), indicating that Vfr can activate *cas1* promoter. To determine whether Vfr directly controls *cas1* promoter activity, we designed and generated a *cas1* promoter-fragment to perform electrophoretic mobility shift assay (EMSA) with the recombinant His-Vfr proteins. Incubation of the *cas1* promoter with increasing amounts Vfr proteins resulted in the dose-dependent formation of the Vfr/*cas1* promoter complex ([Figure 3](#fig3){ref-type="fig"}H), demonstrating that Vfr directly binds to the *cas1* promoter. Thus, we designed oligonucleotide probes for these sites or mutated the binding motifs ([Figure 3](#fig3){ref-type="fig"}A). EMSA analysis revealed that Vfr bound to the WT Vfr CRE but not to the mutant Vfr CRE ([Figures 3](#fig3){ref-type="fig"}G and 3I). To further evaluate whether the Vfr CRE is required for the activation of the *cas1* promoter, we mutated the binding sites in the *cas1* promoter region. Our results showed that activation of the *cas1* promoter was abolished with the mutant Vfr CRE compared with a *lacZ* reporter possessing the intact Vfr CRE in the PA14-WT strain ([Figure 3](#fig3){ref-type="fig"}G). Taken together, these results demonstrate that Vfr requires the specific Vfr CRE to activate the *cas* operon, which is responsible for the functionality of type I-F CRISPR-Cas in PA14.Figure 3Vfr Promotes CRISPR-Cas Activities by Binding CRISPR-Cas Promoter Operon(A) The PA14 *cas1* promoter contains a *cis*-response element (CRE) similar to Vfr-binding consensus site in *P. aeruginosa* PAO1. A mutated CRE shown in red for investigating Vfr binding (Vfr CRE-Δ). Star represents bases matching the consensus.(B) Heatmap for relative transcripts of *cas1*, *cas3*, and *csy1-4* in PA14-WT, PA14-Δ*vfr*, and PA14-Δ*vfr/p-vfr* quantified by qRT-PCR. Data were normalized with 16sRNA expression as an internal control.(C) Transformation efficiency of CRISPR-targeted plasmids in the PA14-WT or PA14-Δ*vfr* mutant.(D) New spacer acquisition (CRISPR expansion) in CRISPR array 1 or 2 locus was quantified in PA14-WT, PA14-Δ*vfr*, and PA14-Δ*vfr/p-vfr* mutant strains by PCR-based analysis.(E) DMS3~100%~ and DMS3-T255C phages grew on bacterial lawns of PA14-WT, PA14-Δ*vfr*, PA14-Δ*vfr/p-vfr*, and PA14-ΔTCR.(F) Expression of the integrative *cas1-p-lacZ* for *cas* operon reporter in PA14-WT and PA14-Δ*vfr* mutant. Dashed lines indicate growth in lysogeny broth (LB); solid lines represent *cas1* promoter activity.(G) Expression of the *cas1* promoter or the *cas1* promoter containing mutated Vfr-binding sites (*cas1-*Δ*-p*) in the PA14-WT, PA14-Δ*vfr*, or PA14-Δ*vfr/p-vfr* mutant measured at 24 h.(H) EMSA for binding of Vfr to the *cas* operon. Left, interaction between Vfr and *cas1* promoter; right, mutation analysis of the Vfr-binding site in *cas1* promoter binding to Vfr.(I) EMSA for Vfr binds to the region of Vfr CRE or CRE-Δ probe.Data shown are the means ± SEM (n = 3) (one-way ANOVA plus Tukey test, \*\*p \< 0.01; \*p \< 0.05).

Deletion of CdpR in PA14 exhibited a pronounced increase in the expression of *vfr* compared with the WT strain ([Figure 4](#fig4){ref-type="fig"}A). To further investigate the influence of Vfr in the CdpR-mediated CRISPR-Cas function, PA14-Δ*cdpR*, PA14-Δ*vfr* single mutant, and PA14-Δ*cdpR*/Δ*vfr* double mutant strains were generated and the expression of the CRISPR-Cas system was quantified in these strains. The increase of *cas1*, *cas3*, *csy1-4* expression and *cas1* promoter activity in PA14-Δ*cdpR* were abolished by deletion of *vfr*, but complementation of *vfr* to the PA14-Δ*cdpR*/Δ*vfr* mutant restored to the WT-PA14 or PA14-Δ*cdpR* levels ([Figures 4](#fig4){ref-type="fig"}B and 4C), indicating that Vfr profoundly influences the CdpR-mediated regulation of the CRISPR-Cas system. Furthermore, transformation efficiency analysis demonstrated that CRISPR-Cas interference was decreased in the PA14-Δ*cdpR*/Δ*vfr* strain compared with the PA14-Δ*cdpR* strain but restored to the control level by vfr complementation (PA14-Δ*cdpR*/Δ*vfr*/*p-vfr* strain, [Figure 4](#fig4){ref-type="fig"}D). Moreover, expansion of the CRISPR array was not detectable in the PA14-Δ*cdpR*/Δ*vfr* strain compared with the PA14-WT and PA14-Δ*cdpR* strains ([Figure 4](#fig4){ref-type="fig"}E). Taken together, these data elucidate that CdpR connects Vfr to regulate the interference and spacer acquisition by type I-F CRISPR-Cas systems ([Figure 4](#fig4){ref-type="fig"}F).Figure 4Vfr along with CdpR Modulates Activity of CRISPR-Cas Loci through Binding Cas Promoter(A) qRT-PCR analysis of *vfr* in PA14-WT, PA14-Δ*cdpR*, and PA14-Δ*cdpR/p-cdpR*.(B) Heatmap for *cas*-related transcripts in PA14-WT, PA14-Δ*cdpR*, PA14-Δ*vfr*, PA14-Δ*cdpR*/Δ*vfr*, and PA14-Δ*cdpR*/Δ*vfr/p-vfr*.(C) *cas1-p-lacZ* and *cas1-*Δ-*p-lacZ* activity in the PA14-WT, PA14-Δ*cdpR*, PA14-Δ*vfr*, PA14-Δ*cdpR*/Δ*vfr*, and PA14-Δ*cdpR*/Δ*vfr/p-vfr* mutant strains were measured at 24 h post inoculation.(D) Transformation efficiency of CRISPR-targeted plasmids in the PA14-WT or mutant strains.(E) Integration of new spacers into CRISPR array loci detected in PA14-Δ*cdpR* strains with or without the deletion of *vfr*.(F) Schematic of the CdpR cooperating with Vfr to control CRISPR-Cas system functionality.Bars, means ± SEM; n = 3; \*\*p \< 0.01; \*p \< 0.05 (one-way ANOVA plus Tukey test).

QS LasI/RhlI Participate in the CdpR/Vfr-Mediated Regulation of CRISPR-Cas Functionality {#sec2.5}
----------------------------------------------------------------------------------------

We investigated whether Vfr affects the CdpR-mediated regulation of CRISPR-Cas system via QS (LasI/RhlI) and found that the Δ*lasI*/Δ*rhlI* double mutant negatively impacted *cas1* promoter activity ([Figure 5](#fig5){ref-type="fig"}A). The enhanced activity of *cas1* promoter in the PA14-Δ*cdpR* was abolished by double deletion of *lasI*/*rhlI* ([Figure 5](#fig5){ref-type="fig"}B). In addition, the expression of *vfr* was markedly increased by adding QS autoinducers: 3OC12-HSL and C4-HSL ([Figure 5](#fig5){ref-type="fig"}C), whereas baicalein blocked this effect of QS signals, resulting in a modest reduction in *vfr* expression compared with the WT strain ([Figure 5](#fig5){ref-type="fig"}C). Similarly, the *cas1* promoter activity was enhanced by the QS autoinducers but decreased by the QS inhibitor baicalein ([Figure 5](#fig5){ref-type="fig"}D). Furthermore, the increase of *cas1* promoter activity was abolished by the autoinducers when Vfr CRE was mutated ([Figure 5](#fig5){ref-type="fig"}D). These results strongly indicate that QS signals regulate Vfr to positively influence the *cas* operon. Since LasI and RhlI synthesize 3OC12-HSL and C4-HSL, respectively ([@bib39]), we delved into the relationship of LasI/RhlI with Vfr. As expected, disruption of *lasI*/*rhlI* attenuated *vfr* expression ([Figure 5](#fig5){ref-type="fig"}E). Addition of 3OC12-HSL and C4-HSL to the cultured PA14-Δ*lasI*/Δ*rhlI* strain increased *vfr* expression ([Figure 5](#fig5){ref-type="fig"}F), which is consistent with reduction of the *cas* operon activity in the absence of LasI/RhlI ([Figures 5](#fig5){ref-type="fig"}A and 5G). These findings proved that LasI and RhlI help in the production of QS autoinducers to activate *vfr*. Collectively, our data indicate that CdpR represses QS regulators to achieve the modulation of CRISPR-Cas functionality in a Vfr-dependent manner ([Figure 5](#fig5){ref-type="fig"}H).Figure 5QS LasI/RhlI Participate in CdpR-Mediated Regulation of CRISPR-Cas System via Vfr(A) Expression of *cas*1*-p*-*lacZ* reporter in PA14-WT, PA14-Δ*lasI*, PA14-Δ*rhlI*, and PA14-Δ*lasI*/Δ*rhlI* at 24 h post inoculation.(B) *cas1-p-lacZ* activity in PA14-WT, PA14-Δ*cdpR*, and PA14-cdpR/ΔlasI/ΔrhlI backgrounds at 24 h post inoculation.(C) qRT-PCR analysis of vfr in PA14-WT with or without QS autoinducers (2 μM 3OC12-HSL and 10 μM C4-HSL) or inhibitor (100 μM baicalein).(D) Expression of the integrative *cas1-p-lacZ* and *cas1-*Δ-*p-lacZ* for *cas* operon reporter in PA14-WT in the presence or absence of QS autoinducers or inhibitor.(E) Relative transcripts of *vfr* in PA14-WT and PA14-Δ*lasI*/Δ*rhlI* quantified by qRT-PCR.(F) qRT-PCR analysis of *vfr* in the PA14-Δ*lasI*/Δ*rhlI* background with or without QS autoinducers.(G) Expression of the integrative *cas1-p-lacZ* for *cas* operon reporter in PA14-Δ*lasI*/Δ*rhlI* mutant in the absence or presence of QS autoinducers.(H) Schematic of CdpR repressing QS regulators LasI/RhlI to inhibit CRISPR-Cas system functionality via Vfr.Bars, means ± SEM; n = 3; \*\*p \< 0.01; \*p \< 0.05 (one-way ANOVA plus Tukey test).

CdpR Inhibits CRISPR-Cas Systems to Regulate Endogenous Transcription {#sec2.6}
---------------------------------------------------------------------

Running a constantly active CRISPR-Cas system imposes a risk of cleaving the bacterial own mRNA or DNA as a CRISPR spacer may happen to be partially complementary to their own sequences, which may lead to autoimmunity. Based on the mechanism of RNA binding for PA14 CRISPR-Cas systems as recently described ([@bib29], [@bib38]), the crRNAs of type I-F CRISPR-Cas system in PA14 may potentially target 189 endogenous transcripts ([Figure 6](#fig6){ref-type="fig"}A and [Table S1](#mmc2){ref-type="supplementary-material"}). To investigate whether CdpR-mediated alterations of CRISPR-Cas affect endogenous genes at the transcription level, we probed crRNA-guided recognition of *glpF* and *cysT* mRNA based on 5′-GGN-3′ of PAM near its 5′-end but not 3′-end among these 189 candidate endogenous transcripts, which may be potentially recognized by PA14 CRISPR-Cas ([Figures 6](#fig6){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}). The PA14-ΔTCR mutant strain lacking *cas* genes showed increased transcripts of *glpF* or *cysT* compared with the PA14-WT strain, but this was restored similarly to the WT levels in the complemented strain PA14-ΔTCR/p-TCR. These results argue that CRISPR-Cas systems are indeed involved in the targeted regulation of endogenous genes. Furthermore, the expression of *glpF* or *cysT* transcripts was markedly repressed in PA14-Δ*cdpR* compared with the PA14-WT strain but was not changed in PAO1-Δ*cdpR* compared with the PAO1-WT strain ([Figures 6](#fig6){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}A) that does not possess CRISPR-Cas systems and serves as another negative control. We then examined the expression of *phzM*, which is not a target for the crRNAs, as additional control, and found that it had not been altered in the different strains ([Figure S5](#mmc1){ref-type="supplementary-material"}B).Figure 6CdpR Inhibits Endogenous RNA Cleavage Mediated by CRISPR-Cas(A) Graphical representation of the targeted position of PA14 crRNA spacers in the genome (orange). Rectangular columns show the number of spacers matching the mRNA of endogenous genes.(B) Homology comparison between the mRNA sequences of endogenous genes (*glpF*) and CRISPR array 1 spacer 1 in PA14-WT. Transcripts of endogenous genes in PA14*-*WT and mutant strains at the same cell density quantified by qPCR. Data were normalized with 16sRNA or housekeeping gene *pheS* expression as an internal control.(C) Overview of Co-IP with anti-His tag antibody combined with northern blot to identify endogenous transcripts binding to the CRISPR-Cas system. Northern blot analysis of *glpF* mRNA in the indicated strains (1: PA14-WT; 2: PA14-Δ*cdpR*; 3: PA14-Δ*cdpR/p-cdpR*; 4: PA14-WT/cas3-6xHis; 5: PA14-Δ*cdpR/cas3-6xHis*; 6 PA14-Δ*cdpR*/*p-cdpR*/cas3-6xHis; 7: PA14-WT; 8: PA14-Δ*cdpR*; 9: PA14-Δ*cdpR/p-cdpR*; 10: PA14-WT/*csy3-6xHis*; 11: PA14-Δ*cdpR/csy3-6xHis*; 12 PA14-Δ*cdpR*/*p-cdpR*/csy3-6xHis). RNAs determined with radiolabeled oligonucleotide probes.(D) Single-strand glpF RNA subjected to *in vitro* digestion by purified, recombinant Cas3 and Csy complex.(E) Nuclease-dead Cas3 has no effect on *glpF* mRNA cleavage.(F) Effect of crRNA-target RNA mismatch on the seed-region base-pairing sitting with glpF mRNA subjected to *in vitro* digestion by Cas3-Csy complexes.Data shown are the means ± SEM (n = 3) (one-way ANOVA plus Tukey test; \*\*p \< 0.01; \*p \< 0.05).

To precisely gauge the capacity for endogenous RNA targeting by CRISPR-Cas, we employed a co-immunoprecipitation (Co-IP) approach combined with northern blot analysis ([Figure 6](#fig6){ref-type="fig"}C). The *cas3* gene was tagged with 6xHis in PA14-WT, PA14-Δ*cdpR*, and PA14-Δ*cdpR/p-ΔcdpR* strains. We performed a Co-IP on the *cas3*-6xHis strains ([Figures 6](#fig6){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}C, lanes 4--6) and the untagged strains as a control ([Figures 6](#fig6){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}C, lanes 1--3) to obtain RNA for northern blot. We identified *glpF* and *cysT* mRNA fragments with enrichment in Cas3-6xHis Co-IP ([Figures 6](#fig6){ref-type="fig"}C, left and [S5](#mmc1){ref-type="supplementary-material"}C, lane 4) but found no change in *phzM* serving as a negative control ([Figure 6](#fig6){ref-type="fig"}C, right), indicating that Cas3 directly binds to endogenous RNA. Moreover, northern blot showed that endogenous transcripts of *glpF* or *cysT* were more abundant in the PA14-Δ*cdpR* strain than in the WT strain ([Figures 6](#fig6){ref-type="fig"}C-left and [S5](#mmc1){ref-type="supplementary-material"}C, lanes 4--6). Moreover, similar results for the detection of crRNA binding to Cascade complex were observed via Csy3-6xHis Co-IP ([Figure 6](#fig6){ref-type="fig"}C). In addition, cleavage assay showed that a significant amount of *glpF* mRNAs were cleaved *in vitro* by the CRISPR-Cas complex ([Figure 6](#fig6){ref-type="fig"}D). However, glpF mRNA substrates were not cleaved by nuclease-dead Cas3 ( K427A or D576A mutants in DExD/H domain) ([Figure 6](#fig6){ref-type="fig"}E). We also found that the seed-region base-pairing between crRNA and RNA substrates is critical for RNA cleavage, as mutation of these nucleotides results in reduced glpF mRNA cleavage ([Figure 6](#fig6){ref-type="fig"}F). Taken together, these studies suggest that CdpR maintains the endogenous transcripts stabilization by inhibiting the activity of CRISPR-Cas. Overall, these findings demonstrate that CRISPR-mediated repression of endogenous transcripts may be neutralized by CdpR, which may be critical for regulating the abundance of individual mRNA and shaping bacterial transcriptomes.

Discussion {#sec3}
==========

To date, knowledge about the microbial CRISPR-mediated adaptive immunity is rapidly evolving, particularly its primary function in preventing phage infection ([@bib33]). Invasion and expansion of phages are likely to occur with the increase of bacterial cell density and can be monitored by QS surveying ([@bib24]). We uncover that CdpR facilitates the repression of CRISPR-Cas loci via regulation of QS systems. Consistent with this finding, the *cdpR*-deficiency mutant strain exhibits enhanced CRISPR-Cas immunity via QS signaling against phages\' or foreign MGEs\' invasion, indicating that CdpR-repressed QS signals, especially combination with LasI/RhlI axis, modulate the anti-phage mechanism during infection. In short, CdpR together with QS signals adds another layer of organization to bacterial anti-phage intracellular signaling. These analyses also suggest that bacterial intrinsic anti-QS components, such as CdpR, may amplify the risk of viral infection, which reflects the critical virulence ability for QS systems in invasion of hosts, consistent with that self-targeting may be harmful to bacteria ([@bib6]).

Vfr functions as a global regulator of virulence factors in response to environmental cues ([@bib9]). Vfr positively regulates the production of type IV pili (Tfp), type III secretion system (T3SS), and LasR QS system that control the expression of hundreds of additional genes ([@bib1], [@bib43]). In addition, Vfr negatively regulates flagellar gene expression ([@bib9]). We noticed that a consensus Vfr binding sequence located in the *cas* operon region interacts with Vfr to alter expression levels of CRISPR-Cas systems. Furthermore, Vfr is required for the CdpR-mediated regulation of CRISPR-Cas immune function. Moreover, the function of Vfr was activated by QS autoinducers and repressed by QS inhibitors. These data illustrate that CdpR represses QS regulators to inhibit CRISPR-Cas immunity through the Vfr signaling; however, the detailed mechanism remains to be defined.

CRISPR-Cas adaptive immunity widely exists in the bacterial world because of the everlasting viruses-host arm race and/or collaboration ([@bib37]). However, the expression of CRISPR-Cas loci is costly because of the possibility of self-targeting between the spacer and portion of the endogenous genes in the genome that is not part of a CRISPR array ([@bib12], [@bib29]). *P*. *aeruginosa* type I-F CRISPR-Cas systems (Cas3) are reported to cleave the *lasR* RNA, resulting in an impaired immune response by the host ([@bib29]). In accordance, suppression of both *P*. *aeruginosa* biofilm formation and swarming motility by its type I-F CRISPR-Cas system requires the crRNA ([@bib20]). Furthermore, mutation of the *Myxococcus xanthus* type I-C CRISPR-Cas system leads to reduced expression of the FruA response regulator, resulting in markedly impaired sporulation ([@bib4], [@bib52]). *Listeria monocytogenes* type I-A CRISPR-Cas systems enhance virulence by promoting the expression of a ferrous iron transporter ([@bib32], [@bib50]). Moreover, a constantly active CRISPR-Cas system increases chances of accidental incorporation of nucleic acids from the cell\'s own genome to incur self-reactivity and even death ([@bib49]). The burden of CRISPR-Cas systems, such as targeting endogenous RNA/DNA through imperfect complementarity with crRNA guides and cleavage by Cas nucleases, might provide selective pressure to co-evolution of bacteria against CRISPR-Cas adaptive immunity. Since CdpR is a newly discovered repressor that provides inhibitory effects on CRISPR-Cas function, especially inhibition of CRISPR-mediated endogenous mRNA target, it is highly likely that bacteria need to finely tune CRISPR-Cas activity to provide sufficient host defense while minimizing risk of self-targeting.

Discriminating self from non-self to effectively block invaders is a universal requirement of immune systems to function normally without self-destruction. CRISPR-Cas immunity requires a sequence match between invasive nucleic acids and spacers for cleavage of foreign DNA ([@bib33], [@bib51]), and recognition of PAM serves as a mechanism for self- and non-self-discrimination during type I-F CRISPR-Cas interference ([@bib18], [@bib23], [@bib45], [@bib55], [@bib54]). Hence, the PAM sequence of CRISPR motifs is important for new spacer acquisition ([@bib53]). The sequence of PAM such as Cas3 5′-GG-3′ is widespread in *P*. *aeruginosa* chromosomes ([@bib42]). However, the fact is that only about one bacterium in 10 million will gain a spacer from bacterial chromosomal DNA incorporated into CRISPR loci to defend itself ([@bib49]). This suggests that there is an unknown mechanism to repress the efficiency of CRISPR-Cas systems to acquire spacers from self-genome or exert cell signaling to mediate appropriate CRISPR-Cas function. The CRISPR-Cas immunity is tightly controlled, especially limiting spacer integration, providing one approach to decreasing self-targeting ([@bib34], [@bib49]). Our results demonstrate that CdpR represses immunization and immunity of CRISPR-Cas systems, suggesting that bacteria may have evolved a variety of mechanisms to reduce the risk of spacer acquisition from bacterial chromosomal DNA. Inhibiting self-targeting resembles negative immune-regulation or immune tolerance in mammals as a surveillance mechanism to prevent severe tissue destruction or chronic diseases. However, how the self/non-self-discrimination is regulated remains to be fully studied ([@bib27], [@bib37]).

In conclusion, our results demonstrate the importance of bacterial intracellular signaling in coordinating adaptive immunity in prokaryotes. This study puts forward a previously unrecognized mechanism for the regulation of CRISPR-Cas defense systems by CdpR, where an internal negative mediator has not been identified. Our proposed model delineates a series of events that are associated with CdpR action. In this model, CdpR, as a repressor, inhibits the expression and function of CRISPR-Cas systems by hampering the stimulation of QS and Vfr signaling during bacterial defense against MGEs or phages. Furthermore, CdpR inhibits CRISPR-mediated bacterial endogenous cleavage to reduce the risk of self-targeting, which needs to be further investigated. Nevertheless, our study provides the first account on how bacteria utilize virulence regulators to down-regulate CRISPR immune capacity thereby maintaining homeostasis. The negative regulatory mechanism of CRISPR-Cas systems helps balance effective host defense and self-repression by CRISPR-Cas activities. Hence, this fine-tuning of CRISPR-Cas prevents self-targeting to avoid potential autoimmunity and even mortality, while maintaining a robust CRISPR-Cas adaptive immunity.

Limitations of the Study {#sec3.1}
------------------------

In this study, we identify the first intrinsic negative regulator for CRISPR-Cas that directly impacts functional activities of interference and adaptation, which keeps homeostasis while efficiently counteracting ruthless invasion by bacteriophage. However, we also made a number of observations that are intriguing but need to be probed further experimentally: whether CdpR interacts with a protein or binds to nucleic acids involved in CRISPR-Cas immunity; if so, how does it work with Vfr to control the CRISPR-Cas system. Furthermore, it remains unclear how CdpR controls QS signals and which domain is required for this mechanism. Moreover, it is currently unknown if other regulators can promote or repress the activity of CRISPR-Cas adaptive immunity. Finally, whether the possible mechanistic model of Cas3/Csy complexes-mediated RNA cleavage executes new potential function remains to be defined.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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